# Nuvectis Pharma (Nasdaq: NVCT)

> Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company with a development product pipeline that includes a complement Factor B inhibitor (NXP100) for the treatment of diseases caused by dysregulated activity of the complement system, and two kinase inhibitors for the treatment of advanced cancers (NXP900, a SRC/YES1 inhibitor, and NXP200, a paradox breaker BRAF inhibitor).

Key facts:
- Legal name: Nuvectis Pharma, Inc. Exchange and ticker: Nasdaq: NVCT.
- Headquarters: 1 Bridge Plaza, 2nd Floor, Fort Lee, NJ 07024, United States.
- Pipeline: NXP100 (Complement Factor B Inhibitor); NXP900 (SRC/YES1 Kinase Inhibitor); NXP200 (Paradox Breaker BRAF Inhibitor).
- Leadership: Ron Bentsur, Chairman, Chief Executive Officer and President; Enrique Poradosu, PhD, Executive Vice President, Chief Scientific and Business Officer; Shay Shemesh, Executive Vice President, Chief Development and Operations Officer.
- Company contact: Ron Bentsur, Chairman, Chief Executive Officer and President, rbentsur@nuvectis.com, 201-614-3151.
- Media contact: Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com.
- SEC filer: CIK 0001875558 (https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001875558).

Forward-looking statements: see the Cautionary Note Regarding Forward-Looking Statements in the website disclaimer (https://nuvectis.irinbox.com/nuvectis/disclaimer).

## Pages
- [Home](https://nuvectis.irinbox.com/nuvectis/): Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company developing NXP100, NXP900 and NXP200 for complement-related diseases and oncology.
- [Leadership](https://nuvectis.irinbox.com/nuvectis/leadership): Nuvectis Pharma (Nasdaq: NVCT) leadership: biographies of the management team and Board of Directors, led by Chairman, CEO and President Ron Bentsur.
- [Pipeline](https://nuvectis.irinbox.com/nuvectis/pipeline): Nuvectis Pharma (Nasdaq: NVCT) pipeline: NXP100 (complement Factor B inhibitor), NXP900 (SRC/YES1 kinase inhibitor) and NXP200 (paradox breaker BRAF inhibitor).
- [Publications](https://nuvectis.irinbox.com/nuvectis/publications): Nuvectis Pharma (Nasdaq: NVCT) scientific publications and posters on its NXP100, NXP200 and NXP900 programs, grouped by program and available as PDFs.
- [Clinical Trials](https://nuvectis.irinbox.com/nuvectis/trials): Nuvectis Pharma (Nasdaq: NVCT) clinical trials of NXP900 in advanced cancers, including studies with lorlatinib in ALK+ lung cancer and osimertinib in NSCLC.
- [Press Releases](https://nuvectis.irinbox.com/nuvectis/press-releases): Press releases from Nuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on complement-related diseases and oncology.
- [Events & Presentations](https://nuvectis.irinbox.com/nuvectis/presentations): Nuvectis Pharma (Nasdaq: NVCT) investor events, conference presentations and webcasts, with the latest corporate presentation available to download as a PDF.
- [Stock Quote](https://nuvectis.irinbox.com/nuvectis/stock-info): Nuvectis Pharma (Nasdaq: NVCT) stock quote and price chart, with the open, high, low, volume and 52-week range for NVCT shares traded on the Nasdaq.
- [Historical Data](https://nuvectis.irinbox.com/nuvectis/historical-data): Nuvectis Pharma (Nasdaq: NVCT) historical stock prices by trading week: daily open, high, low, close and volume for NVCT shares, plus weekly performance.
- [SEC Filings](https://nuvectis.irinbox.com/nuvectis/sec-filings): SEC filings for Nuvectis Pharma (Nasdaq: NVCT), including annual and quarterly reports, current reports, proxy statements and ownership filings on EDGAR.
- [Email Alerts](https://nuvectis.irinbox.com/nuvectis/email-alerts): Sign up for Nuvectis Pharma (Nasdaq: NVCT) email alerts to receive new press releases and SEC filings from the company directly in your inbox.
- [Contact Us](https://nuvectis.irinbox.com/nuvectis/contact): Contact Nuvectis Pharma (Nasdaq: NVCT) investor relations and media. Company contact: Ron Bentsur, Chairman, CEO and President, in Fort Lee, New Jersey.
- [Governance Documents](https://nuvectis.irinbox.com/nuvectis/governance-documents): Nuvectis Pharma (Nasdaq: NVCT) corporate governance documents, including committee charters and the Code of Business Conduct and Ethics, available as PDFs.
- [Disclaimer](https://nuvectis.irinbox.com/nuvectis/disclaimer): Legal disclaimer for the Nuvectis Pharma (Nasdaq: NVCT) website, covering copyright, currency of information and the note on forward-looking statements.
- [Terms of Use](https://nuvectis.irinbox.com/nuvectis/terms): Terms and conditions of use for the Nuvectis Pharma, Inc. (Nasdaq: NVCT) website, covering acceptance of terms, use of information and limits of liability.
- [Privacy Policy](https://nuvectis.irinbox.com/nuvectis/privacy): Privacy policy for the Nuvectis Pharma, Inc. (Nasdaq: NVCT) website: what information the site collects, how it is used and protected, and how to reach us.

## Latest press releases
- [Nuvectis Pharma to Participate in the Maxim Growth Summit 2026](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20261009-nuvectis-pharma-to-participate-in-the-maxim-growth-summit-20): 2026-10-09
- [Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260924-nuvectis-announces-nxp200-granted-breakthrough-therapy-desig): 2026-09-24
- [Nuvectis Pharma To Participate in Upcoming Investor Conferences](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260903-nuvectis-pharma-to-participate-in-upcoming-investor-conferen): 2026-09-03
- [Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260804-nuvectis-pharma-reports-second-quarter-2026-financial-result): 2026-08-04
- [Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260723-correction-title-correction-nuvectis-announces-marketing-app): 2026-07-23
- [Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260723-ciprocopan-nxp100-receives-marketing-approval-in-china-for-t): 2026-07-23
- [Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260630-nuvectis-pharma-announces-pricing-of-100-million-public-offe): 2026-06-30
- [Nuvectis Pharma Announces Proposed Public Offering of Common Stock](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260629-nuvectis-pharma-announces-proposed-public-offering-of-common): 2026-06-29
- [Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260622-nuvectis-announces-strategic-portfolio-expansion-via-license): 2026-06-22
- [Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260514-nuvectis-pharma-inc-to-participate-in-the-hc-wainwright-4th): 2026-05-14
- [Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260505-nuvectis-pharma-inc-reports-first-quarter-2026-financial-res): 2026-05-05
- [Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260331-nuvectis-pharma-announces-upcoming-presentations-for-nxp900): 2026-03-31
- [Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20260211-nuvectis-pharma-inc-reports-2025-financial-results-and-busin): 2026-02-11
- [Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20251217-nuvectis-pharma-announces-the-initiation-of-the-phase-1b-stu): 2025-12-17
- [Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20251125-nuvectis-pharma-to-host-a-virtual-key-opinion-leader-meeting): 2025-11-25
- [CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20251104-correction-nuvectis-pharma-inc-reports-third-quarter-2025-fi): 2025-11-04
- [Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20251104-nuvectis-pharma-inc-reports-third-quarter-2025-financial-res): 2025-11-04
- [Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20251027-nuvectis-pharma-provides-poster-presentation-highlights-for): 2025-10-27
- [Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20251016-nuvectis-pharma-announces-upcoming-presentations-for-nxp900): 2025-10-16
- [Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors](https://nuvectis.irinbox.com/nuvectis/press-releases/nvct-20250925-nuvectis-pharma-appoints-biotech-executive-juan-sanchez-md-t): 2025-09-25

## Optional
- [Full text of this site](https://nuvectis.irinbox.com/llms-full.txt)
- [Sitemap](https://nuvectis.irinbox.com/sitemap.xml)
- [SEC EDGAR filings for Nuvectis Pharma, Inc.](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001875558)
- [Nasdaq listing](https://www.nasdaq.com/market-activity/stocks/nvct)